Eloxx pharmaceuticals, inc. (ELOX)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Mar'12Dec'11Jun'11Mar'11Dec'10Sep'10
Operating expenses:
Research and development

4,549

5,682

6,801

7,340

6,019

6,530

5,415

4,150

4,394

8,168

3,280

2,595

2,355

207

280

410

576

594

601

841

235

1,371

2,120

830

966

730

810

489

492

591

513

540

751

585

800

798

1,536

Licensing Revenue

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

37

37

37

37

0

0

0

0

0

100

0

0

0

0

0

-

-

-

-

-

Revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

200

-

-

-

-

General and administrative

5,224

5,806

5,978

6,971

5,958

7,584

5,945

9,560

3,393

1,121

720

584

277

300

480

286

331

401

587

115

1,027

1,253

774

806

1,162

858

856

506

551

708

732

567

904

667

567

706

668

Restructuring charges

3,994

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Reverse merger related expenses

-

-

-

-

-

0

0

-167

761

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on sale of patents

-

-

-

-

-

-

-

-

-

-

-

0

0

0

149

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

13,767

11,488

12,779

14,311

11,977

14,114

11,360

13,543

8,548

10,579

4,000

3,179

2,632

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Impairment of goodwill

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

Impairment of goodwill

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

2,980

2,800

-

-

0

8,121

-

-185

0

0

185

0

0

0

0

0

0

-

-

-

-

Impairment of acquired R&D

-

-

-

-

-

-

-

-

-

-

-

-1,000

0

1,000

1,600

700

1,000

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Impairment and write-off of patents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-2,290

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

-

-

-

-

-

-

-

-

-

-

-

-1,849

341

1,507

2,210

1,396

4,889

3,795

1,188

956

1,262

10,747

5,185

3,677

2,128

1,588

1,852

1,060

1,044

1,300

1,246

1,108

1,656

2,840

1,367

1,505

2,205

Loss from operations

-13,767

-11,488

-12,779

-14,311

-11,977

-14,114

-11,360

-13,543

-8,548

-10,579

-4,000

-3,179

-2,632

-1,507

-2,210

-1,396

-4,889

-3,758

-1,151

-919

-1,224

-10,747

-5,185

-3,677

-2,128

-1,588

-1,752

-1,060

-1,044

-1,300

-1,246

-1,108

-1,456

-2,840

-1,367

-1,505

-2,205

Financial and other expenses

-

-

-

-

-

-

-

-

-

-

-

-

46

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of stock right

-

-

-

-

-

-

-

-

-

-

-

-223

0

223

428

-61

742

-448

22

12

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other expense (income), net

-179

-145

-96

-138

60

209

199

137

-43

-

-40

-699

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

0

-4

-111

Grant income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

-

-

244

-

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-96

0

96

208

25

667

351

948

3

0

0

0

-

-

-

-

99

227

64

-20

-

-

-

-

-

-

Change in fair value of note derivative

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock issuance for anti-dilution right

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Modification of warrant exercise price

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Fair value - warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

76

-39

-

-16

149

319

Sale of state income tax loss - net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

-

-

-

-

Other noncash (expense) income, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

-

-

-

-

Loss on settlement of warrant liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-939

0

0

-785

-

-

-

-

-

-

Loss on extinguishment of debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

-

-

-

-

Amortization of debt discount and financing costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

-

-

-

-

Interest expense - convertible notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

-

-

-

-

Interest expense

-

-

-

-

-

-

-

-

-

-

-

55

-53

-1

-0

-0

0

-0

-0

-3

-2

0

1

2

-17

-30

-31

-30

-19

-34

-33

-27

-32

-27

-21

-21

-18

Loss before income taxes

-

-

-

-

-

-

-

-

-

-

-

3,255

-2,066

-1,189

-1,573

-1,432

-3,479

-3,855

-180

-

-1,227

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Provision for income taxes

-

-

-

-

-

-

-

-

-

-

-

400

0

-400

-640

-280

-400

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-13,946

-11,633

-12,875

-14,449

-11,917

-14,027

-11,161

-13,406

-8,591

-10,618

-4,040

-3,878

-2,678

-789

-933

-1,152

-3,079

-3,855

-180

-906

-1,227

-10,746

-5,183

-3,674

-2,146

-1,619

-1,784

-1,930

-836

-1,269

-2,085

-1,060

-1,527

-2,711

-1,405

-1,136

-2,015

Net loss per share, basic and diluted

-0.35

-0.29

-0.32

-0.40

-0.33

-0.40

-0.32

-0.42

-0.31

-1.83

-1.15

-1.04

-0.73

-0.04

-0.05

-0.06

-0.15

-0.19

-0.02

-0.06

-0.09

-0.78

-0.38

-0.40

-0.87

-0.48

-0.78

-0.80

-0.68

-1.11

-2.52

-0.02

-0.02

-0.04

-0.02

-0.03

-0.05

Weighted average number of shares of common stock used in computing net loss per share, basic and diluted

40,074

40,119

39,944

36,278

35,910

35,373

35,005

31,839

27,527

7,286

4,208

4,205

4,205

20,662

20,496

20,443

20,420

20,420

20,006

15,996

13,958

13,866

13,846

10,349

5,806

3,443

2,307

1,774

1,446

1,169

1,074

88,942

80,832

-

-

-

-

Comprehensive loss:
Net loss

-13,946

-11,633

-12,875

-14,449

-11,917

-14,027

-11,161

-13,406

-8,591

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other comprehensive income (loss):
Change in unrealized gain (loss) on available-for-sale securities

47

6

-12

23

1

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Preferred dividends

-

-

-

-

-

-

-

-

-

-

-

-24

8

15

9

7

9

14

148

797

9

17

14

1,709

2,877

20

21

64

150

23

624

419

127

239

716

675

1,006

Net loss applicable to common shares

-

-

-

-

-

-

-

-

-

-

-

2,880

-2,075

-805

-943

-1,159

-3,088

-3,869

-329

-1,704

-1,236

-10,763

-5,198

-5,383

-5,024

-1,640

-1,805

-1,995

-986

-1,293

-2,709

-1,480

-1,655

-2,951

-2,121

-1,812

-3,021

Other comprehensive loss

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

0

0

0

0

0

0

0

0

0

0

0

0

-

-

-

-

-

Comprehensive loss

-13,899

-11,627

-12,887

-14,426

-11,916

-14,027

-11,161

-13,406

-8,591

-

-

-

-2,075

-805

-943

-

-3,088

-3,869

-329

-

-1,236

-10,763

-5,198

-5,383

-5,024

-1,640

-1,805

-1,995

-986

-1,293

-2,709

-1,480

-

-

-

-

-

Basic and diluted weighted-average number of common shares outstanding

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

75,284

67,978

56,930